

# Maternal postpartum plasma folate status and preterm birth in a high-risk US population

Bolanle Olapeju<sup>1,2</sup>, Ahmed Saifuddin<sup>1</sup>, Guoying Wang<sup>1</sup>, Yuelong Ji<sup>1</sup>, Xiumei Hong<sup>1</sup>, Ramkripa Raghavan<sup>1</sup>, Amber Summers<sup>2</sup>, Amaris Keiser<sup>3</sup>, Hongkai Ji<sup>4</sup>, Barry Zuckerman<sup>5</sup>, Christina Yarrington<sup>6</sup>, Lingxin Hao<sup>7</sup>, Pamela J Surkan<sup>8</sup>, Tina L Cheng<sup>3</sup> and Xiaobin Wang<sup>1,3,\*</sup>

<sup>1</sup>Department of Population, Family and Reproductive Health, Center on Early Life Origins of Disease, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA: <sup>2</sup>Center for Communication Programs, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA: <sup>3</sup>Department of Pediatrics, Johns Hopkins University School of Medicine, 615 N. Wolfe Street, E4132, Baltimore, MD 21205-2179, USA: <sup>4</sup>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA: <sup>5</sup>Department of Pediatrics, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA: <sup>6</sup>Department of Obstetrics and Gynecology, Boston University School of Medicine, Boston, MA, USA: <sup>7</sup>Department of Sociology, Johns Hopkins University, Baltimore, MD, USA: <sup>8</sup>Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

Submitted 8 March 2018: Final revision received 5 October 2018: Accepted 17 October 2018: First published online 29 November 2018

## Abstract

**Objective:** While maternal folate deficiency has been linked to poor pregnancy outcomes such as neural tube defects, anaemia and low birth weight, the relationship between folate and preterm birth (PTB) in the context of the US post-folic acid fortification era is inconclusive. We sought to explore the relationship between maternal folate status and PTB and its subtypes, i.e. spontaneous and medically indicated PTB.

**Design:** Observational study.

**Setting:** Boston Birth Cohort, a predominantly urban, low-income, race/ethnic minority population at a high risk for PTB.

**Participants:** Mother–infant dyads ( $n$  7675) enrolled in the Boston Birth Cohort. A sub-sample ( $n$  2313) of these dyads had maternal plasma folate samples collected 24–72 h after delivery.

**Results:** Unadjusted and adjusted logistic regressions revealed an inverse relationship between the frequency of multivitamin supplement intake and PTB. Compared with less frequent use, multivitamin supplement intake 3–5 times/week (adjusted OR (aOR) = 0.78; 95% CI 0.64, 0.96) or >5 times/week (aOR = 0.77; 95% CI 0.64, 0.93) throughout pregnancy was associated with reduced risk of PTB. Consistently, higher plasma folate levels (highest *v.* lowest quartile) were associated with lower risk of PTB (aOR = 0.74; 95% CI 0.56, 0.97). The above associations were similar among spontaneous and medically indicated PTB.

**Conclusions:** If confirmed by future studies, our findings raise the possibility that optimizing maternal folate levels across pregnancy may help to reduce the risk of PTB among the most vulnerable US population in the post-folic acid fortification era.

## Keywords

Folate status  
Preterm birth

Multivitamin supplementation

Preterm birth (PTB; birth before 37 completed weeks of gestation) has been recognized as one of the most pressing challenges to maternal and child health in the USA and worldwide<sup>(1)</sup>. The role of maternal nutrition remains a promising but understudied area of investigation in the identification of important and modifiable risk factors for PTB.

Folates are a group of naturally occurring water-soluble B vitamins involved in biological reactions needed for fetal

and placental growth such as DNA synthesis, repair and methylation<sup>(2)</sup>. Maternal folate deficiency is a modifiable nutritional status that has been linked with adverse pregnancy outcomes such as neural tube defects, congenital anomalies, low birth weight, maternal megaloblastic anaemia and pre-eclampsia<sup>(3–5)</sup>. Folic acid is a synthetic form of folate that is used in multivitamin supplements and grain product fortification. Despite the establishment of

\*Corresponding author: Email xwang82@jhu.edu

national folate intake recommendations and mandatory folic acid fortification programmes in the USA since 1998<sup>(6,7)</sup>, folate consumption is still of public health significance as data suggest that 25% of women of reproductive age have insufficient folate levels<sup>(8)</sup>.

To date, much attention has been paid to the role of periconception folate intake to prevent neural tube defects in offspring (a first-trimester event)<sup>(9–12)</sup>. However, considerable knowledge gaps remain regarding the role of folate in PTB (a third-trimester event). A population-based analysis demonstrated reduced PTB risk after the implementation of mandatory folic acid fortification in the USA<sup>(13)</sup>. Some US studies have found an association between lower folate status and PTB<sup>(14–18)</sup>, while other studies found no association<sup>(19,20)</sup>. These mixed results may be due to variations across studies in terms of sociodemographic characteristics of the study population, whether the studies were conducted prior to or after the mandatory folic acid fortification programme, differences in definitions and measurement of folate status (self-reported intake *v.* biomarkers) and/or timing of folic acid administration (preconception *v.* specific trimesters). The optimal timing of folic acid intake in relation to PTB remains unclear; *i.e.* whether there is a critical window of folic acid intake such as the periconception period (as has been demonstrated in the folate–neural tube defects relationship) *v.* during a specific trimester of gestation, given PTB is a later event. To date, most relevant studies were based on self-report of folic acid supplementation, which is known to be imprecise and associated with large variation in plasma folate levels, a biomarker of folate nutritional status<sup>(21)</sup>. There is a need for contemporary post-folic acid fortification studies that examine the associations between folic acid intake as well as folate biomarkers and PTB and how the association between folate status and PTB varies by PTB subtypes, *i.e.* spontaneous *v.* medically indicated (induced) PTB, in high-risk US populations.

Our study sought to address the aforementioned gaps in understanding of the association between maternal folate status and PTB in a large, predominantly urban low-income minority birth cohort in the USA. Specifically, we examined the relationship between PTB and self-reported preconception (6 months prior to pregnancy) and pregnancy multivitamin supplementation (during each trimester), as well as biomarker measures of maternal plasma folate at delivery. We also explored whether the associations differed for spontaneous *v.* medically indicated PTB.

## Participants and methods

### Study population

We analysed data from the Boston Birth Cohort study which commenced in 1998 and is ongoing to date<sup>(22,23)</sup>. Our data set included 8494 mother–infant dyads enrolled in the study from 1998 to 2014. The Boston Birth Cohort

is registered at <https://www.clinicaltrials.gov/ct2/show/NCT03228875>. The initial and continuation of the study protocol were approved by the institutional review boards of Boston University Medical Center and Johns Hopkins Bloomberg School of Public Health.

Mothers who delivered at the Boston Medical Center, which serves a predominantly low-income, minority, inner-city patient population, were recruited 24–72 h after delivery while still hospitalized. Of note, the length of stay in hospitals after childbirth in the USA is 2 d for vaginal delivery and 4 d for caesarean section<sup>(24,25)</sup>. Cases were defined as mother–infant dyads with singleton, live, low-birth-weight (<2500 g) or preterm infants (<37 weeks of gestation) regardless of birth weight. Controls were defined as mother–infant dyads with singleton, live, term infants with birth weight of 2500 g or more. Of note, the present paper specifically examines PTB *v.* term birth, regardless of birth weight.

### Data collection

After informed consent was obtained, the study staff collected the epidemiological data, clinical data and maternal venous blood and placental samples. Epidemiological data were collected within 24–72 h postpartum via an in-person maternal questionnaire interview. Clinical data were abstracted from medical records using a standardized form. Plasma folate levels were measured in a sub-sample of the maternal blood samples obtained within 24–72 h postpartum from mothers who continued to receive care at Boston Medical Center.

### Definition of key variables

PTB was defined as delivery before 37 completed weeks of gestation. Gestational age was determined using an algorithm based on the first day of the last menstrual period and the results of early ultrasound (<20 weeks of gestation), as previously published<sup>(23)</sup>.

Multivitamin supplement intake was determined during the maternal interview based on responses to the following questions: ‘Did you take prenatal vitamins prescribed by your doctor?’ and ‘Did you take any over-the-counter multivitamins?’ during pre-pregnancy (6 months prior to conception), first trimester (day 1 to day 90 of pregnancy), second trimester (day 91 to day 180 of pregnancy), third trimester (day 181 of pregnancy to birth)? Response categories included: none, 1 time per week, 2 times per week, 3–5 times per week and almost daily. Based on responses to these two questions, preconception multivitamin intake was dichotomized (none *v.* any). Intake for each trimester as well as across all trimesters was divided into the following categories: none, 1–2 times/week, 3–5 times/week and almost daily. In the USA, prenatal or over-the-counter multivitamins typically contain 800 or 400 µg of folic acid, respectively, and are to be taken daily; however, a majority of mothers enrolled in the cohort received

prenatal care and were advised to take prenatal vitamins which contain 800 µg of folic acid<sup>(26)</sup>. A continuous measure of overall multivitamin supplement intake across all trimesters (henceforth referred to as the 'multivitamin supplement intake index') was developed by adding multivitamin intake across the three trimesters to create a composite index of multivitamin supplement intake across pregnancy. For each trimester, frequency of intake was coded as none = 0, 1–2 times/week = 1, 3–5 times/week = 3 and almost daily = 4. Thus, the composite index ranged from 0 to 12.

Plasma folate concentrations were measured using chemiluminescent immunoassay with diagnostic kits (Shenzhen New Industries Biomedical Engineering Co., Ltd, Shenzhen, China) using a Beckman Coulter ACCESS Immunoassay System (Beckman-Coulter Canada, Mississauga, Canada)<sup>(27)</sup>. Plasma folate levels were assessed as: (i) a continuous variable in nmol/l; (ii) quartiles of plasma folate levels; and (iii) categorizations as per the WHO guidelines (folate deficiency/insufficiency, <13.5 nmol/l; normal, 13.5–45.3 nmol/l; elevated, >45.3 nmol/l)<sup>(28)</sup>.

Other covariates included sociodemographic factors, such as: maternal age at delivery (<20, 20–34, ≥35 years); maternal education (≤ elementary, high school, ≥ college); race/ethnicity (non-Hispanic Black, non-Hispanic White, Hispanic, Other); marital status (unmarried *v.* married); parity (nulliparous *v.* multiparous); receipt of public assistance including WIC (Special Supplemental Nutrition Program for Women, Infants, and Children), food stamps, AFDC (Aid to Families with Dependent Children, now known as TANF (Temporary Aid to Needy Families)), housing assistance or fuel assistance (yes *v.* no); and maternal nativity (US born *v.* foreign born). Behavioural risk factors included: alcohol use (never *v.* any); smoking status (never used, ever used, used in pregnancy); and stress (an indicator for mother's report of life or pregnancy as being 'very' stressful). Biomedical factors from abstracted records included: pre-eclampsia disorders (pre-eclampsia, eclampsia, gestational hypertension, HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome); maternal diabetes (presence of either gestational or pre-gestational diabetes); intra-uterine infection/inflammation (presence of maternal fever or placenta pathology findings of villitis, deciduitis, chorioamnionitis, chorionitis, subchorionitis, funisitis, free membranitis); and pre-pregnancy BMI (calculated from self-reported height and weight) grouped into four categories (underweight, <18.5 kg/m<sup>2</sup>; normal weight, 18.5–24.9 kg/m<sup>2</sup>; overweight, 25.0–29.9 kg/m<sup>2</sup>; obesity, ≥ 30.0 kg/m<sup>2</sup>).

### Statistical analyses

All analyses were conducted using the statistical software package Stata version 14. Preliminary data analysis was performed in the full sample (*n* 7576) of all enrolled

women with multivitamin supplement intake data and the plasma folate sub-sample (*n* 2313) of these women who received follow-up paediatric care at Boston Medical Center. The  $\chi^2$  test for categorical variables and *t* test for continuous variables were used to compare maternal characteristics by PTB status. Cronbach's  $\alpha$  was used to ensure the reliability of the scale 'multivitamin supplement intake index' (Cronbach's  $\alpha$  = 0.87). Unadjusted and adjusted logit regressions were used to graph the probability of PTB by plasma folate level. Crude and adjusted logistic regressions were used to explore the relationship between PTB and self-reported multivitamin supplement intake and plasma folate level. Supplemental analyses were conducted for the PTB subgroups of spontaneous and medically indicated PTB. All *P* values in the analyses were two-sided and the Type I error rate was set at 0.05.

### Results

The present study was based on a full sample of 7576 women with complete multivitamin supplement intake information from 6 months before conception to the third trimester of pregnancy and a sub-sample (*n* 2313) with plasma folate samples collected at delivery. Those included in the full sample and those who had plasma folate data had similar baseline characteristics, except for a higher proportion of non-Hispanic Black mothers and PTB in the sub-sample.

Table 1 displays the maternal characteristics for the total study population and plasma folate sub-sample (maternal characteristics by PTB subtype are presented in the online supplementary material, Supplemental Table 1). In the full sample, 27% of women had a preterm delivery. Compared with women with term births, women with PTB were more likely to be non-Hispanic Black, older, US-born, unmarried, cigarette smokers, alcohol consumers and report a very stressful life or pregnancy. These women were also likely to have had pre-eclampsia disorders, intra-uterine infection/inflammation, diabetes mellitus and be obese/overweight.

Within the plasma folate sub-sample, 31% of women experienced PTB. The mean and median plasma folate concentration at delivery was 32.3 (SD 20.0) and 28.5 nmol/l, respectively, for PTB; significantly lower than 36.3 (SD 24.7) and 31.5 nmol/l, respectively, for term births. Significant associations between maternal characteristics and PTB that were seen in the total supplement intake sample persisted in the plasma folate sub-sample. Plasma folate was mildly correlated with multivitamin supplement intake in the third trimester ( $\rho$  = 0.10,  $P$  < 0.001). The relationship between plasma folate concentrations and gestational age is presented graphically in the online supplementary material, Supplemental Fig. 1. Every unit increase in plasma folate concentration was associated with a 0.01-week increase in gestational age (95% CI 0.004, 0.016).

**Table 1** Maternal characteristics of the study population: predominantly urban, low-income, minority mother–infant dyads (*n* 7576) enrolled in the Boston Birth Cohort, USA, from 1998 to 2014

Maternal characteristics	Multivitamin supplement sample				Plasma folate sub-sample			
	Term ( <i>n</i> 5507; 73%)		PTB ( <i>n</i> 2069; 27%)		Term ( <i>n</i> 1593; 69%)		PTB ( <i>n</i> 720; 31%)	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
<b>Race/ethnicity</b>								
Non-Hispanic Black*	2764	50.2	1083	52.3	1133	71.1	555	77.1
Non-Hispanic White	645	11.7	275	13.3	65	4.1	27	3.8
Hispanic	1614	29.3	536	25.9	323	20.3	115	16.0
Other	451	8.2	163	7.9	72	4.5	23	3.2
Missing	33	0.6	12	0.6	0	0.0	0	0.0
<b>Age (years)</b>								
< 20	608	11.0	195	9.4	159	10.0	67	9.3
20–34	4053	73.6	1446	69.9	1171	73.5	494	68.6
≥ 35	813	14.8	416	20.1	263	16.5	159	22.1
Missing	33	0.6	12	0.6	0	0.0	0	0.0
<b>Nativity</b>								
Foreign born	3403	61.8	1118	54.0	970	60.9	377	52.4
US born	2029	36.8	935	45.2	596	37.4	338	46.9
Missing	75	1.4	16	0.8	27	1.7	5	0.7
<b>Education</b>								
Less than high school	1680	30.5	623	30.1	434	27.2	204	28.3
High school/GED	1800	32.7	741	35.8	575	36.1	279	38.8
Some/beyond college	1970	35.8	684	33.1	578	36.3	234	32.5
Missing	57	1.0	21	1.0	6	0.4	3	0.4
<b>Marital status</b>								
Married	2038	37.0	698	33.7	564	35.4	225	31.3
Unmarried	3339	60.6	1339	64.7	1019	64.0	488	67.8
Missing	130	2.4	32	1.5	10	0.6	7	1.0
<b>Receipt of public assistance†</b>								
No	856	15.5	354	17.1	208	13.1	112	15.6
Yes	4651	84.5	1715	82.9	1385	86.9	608	84.4
<b>Parity</b>								
Multiparous	3119	56.6	1180	57.0	933	58.6	425	59.0
Nulliparous	2374	43.1	885	42.8	657	41.2	294	40.8
Missing	14	0.3	4	0.2	3	0.2	1	0.1
<b>Cigarette smoking</b>								
Never	4449	80.8	1534	74.1	1321	82.9	545	75.7
Ever	376	6.8	175	8.5	114	7.2	73	10.1
Continued in pregnancy	611	11.1	336	16.2	145	9.1	99	13.8
Missing	17	1.3	24	1.2	13	0.8	3	0.4
<b>Alcohol consumption</b>								
No	4858	88.2	1782	86.1	1431	89.8	644	89.4
Yes	474	8.6	218	10.5	124	7.8	67	9.3
Missing	175	3.2	69	3.3	38	2.4	9	1.3
<b>Stress‡</b>								
No	4404	80.0	1544	74.6	1270	79.7	535	74.3
Yes	1078	19.6	516	24.9	317	19.9	183	25.4
Missing	25	0.5	9	0.4	6	0.4	2	0.3
<b>BMI category§</b>								
Underweight	227	4.1	97	4.7	62	3.9	27	3.8
Normal	2494	45.3	859	41.5	701	44.0	269	37.4
Overweight/obese	2367	43.0	973	47.0	745	46.8	386	53.6
Missing	419	7.6	140	6.8	85	5.3	38	5.3
<b>Pre-eclampsia disorders  </b>								
No	5047	91.6	1582	76.5	1483	93.1	534	74.2
Yes	460	8.4	487	23.5	110	6.9	186	25.8
<b>Intra-uterine infection/inflammation¶</b>								
No	4371	79.4	1557	75.3	1361	85.4	560	77.8
Yes	690	12.5	432	20.9	169	10.6	151	21.0
Missing	446	8.1	80	3.9	63	4.0	9	1.3
<b>Diabetes mellitus</b>								
None	5162	93.7	1850	89.4	1498	94.0	632	87.8
Gestational	220	4.0	124	6.0	53	3.3	49	6.8
Pre-gestational	75	1.4	79	3.8	31	1.9	34	4.7
Missing	50	0.9	16	0.8	11	0.7	5	0.7

Table 1 Continued

Maternal characteristics	Multivitamin supplement sample				Plasma folate sub-sample			
	Term (n 5507; 73%)		PTB (n 2069; 27%)		Term (n 1593; 69%)		PTB (n 720; 31%)	
	n	%	n	%	n	%	n	%
Multivitamin supplement intake preconception								
None	5137	93.3	1940	93.8	1504	94.4	671	93.2
Any	370	6.7	129	6.2	89	5.6	49	6.8

PTB, preterm birth; GED, General Equivalency Diploma.

\*Non-Hispanic Black includes Black, African American, Haitian, Cape Verdian.

†Public assistance is defined as receipt of any of the following: WIC (Special Supplemental Nutrition Program for Women, Infants, and Children), food stamps, AFDC (Aid to Families with Dependent Children, now known as TANF (Temporary Aid to Needy Families)), housing assistance or fuel assistance.

‡Mother's self-report of life or pregnancy being very stressful.

§Underweight, BMI <18.5 kg/m<sup>2</sup>; normal weight, BMI = 18.5–24.9 kg/m<sup>2</sup>; overweight/obesity, BMI ≥ 25.0 kg/m<sup>2</sup>.

|| Pre-eclampsia disorders are defined as the presence of pre-eclampsia, gestational hypertension and HELLP (haemolysis, elevated liver enzymes and low platelets) syndrome.

¶ Intra-uterine infection/inflammation is defined as the presence of maternal fever or placenta pathology findings of villitis, deciduitis, chorioamnionitis, chorionitis, subchorionitis, funisitis and free membranitis.

Table 2 displays the association between self-reported multivitamin supplement intake and PTB (analysis by PTB subtypes is presented in the online supplementary material, Supplemental Table 2). The overall multivitamin supplement intake across pregnancy was significantly associated with PTB. Specifically, each unit increase in the multivitamin supplement intake index reduced the odds of PTB (adjusted OR (aOR)=0.98; 95% CI 0.97, 0.99). As a categorical variable, consistent multivitamin supplement intake (3–5 times/week or >5 times/week) reduced the odds of PTB compared with no intake across pregnancy (aOR=0.78; 95% CI 0.64, 0.96 and aOR=0.77; 95% CI 0.64, 0.93, respectively). The relationship between multivitamin supplement intake across different time points and PTB showed that intake during the preconception period did not reduce PTB odds. Intake during the first trimester (>5 times/week) was associated with a reduction in PTB odds (aOR=0.85; 95% CI 0.73, 0.98). During the third trimester, intake of 3–5 times/week and >5 times/week were associated with lower odds of PTB (aOR=0.75; 95% CI 0.63, 0.85 and aOR=0.74; 95% CI 0.64, 0.87, respectively). There was no significant difference in the odds of PTB among women with consistent multivitamin supplement intake of 1–2 times/week throughout pregnancy compared with no intake throughout pregnancy. Sensitivity analysis presented in Supplemental Table 3 showed a consistent pattern of a relationship of multivitamin supplement intake at all time points with PTB among non-Hispanic Blacks only.

Table 3 displays the unadjusted and adjusted odds of PTB by plasma folate concentration. Each unit and interquartile increase in plasma folate concentration reduced the odds of PTB (aOR=0.99; 95% CI 0.99, 1.00 and aOR=0.88; 95% CI 0.79, 0.97, respectively). This association persisted when plasma folate concentration was categorized. Compared with the lowest quartile (<19.4 nmol/l), the highest quartile of plasma folate

concentration (>43.8 nmol/l) was associated with a reduction in PTB odds of over 25% (aOR=0.74; 95% CI 0.56, 0.79). Similarly, excess plasma folate concentration (>45.3 nmol/l) was associated with reduced odds of PTB (aOR=0.70; 95% CI 0.55, 0.98) compared with normal plasma concentration (13.5–45.3 nmol/l).

Figure 1 displays the association between plasma folate concentration at delivery and probability of PTB, stratified by subtypes. Plasma folate concentration demonstrated a mild curvilinear relationship with overall PTB, a linear relationship with spontaneous PTB and a curvilinear relationship with medically indicated PTB, where higher concentrations of plasma folate were associated with a reduced probability of PTB or its subtypes.

In Table 4, the relationship between plasma folate concentration and spontaneous *v.* medically indicated PTB is presented. The final regression model for medically indicated PTB did not include biomedical risk factors to avoid the introduction of factors potentially in the causal pathway. Each unit increase in plasma folate concentration was associated with reduced odds of spontaneous (aOR=0.99; 95% CI 0.99, 1.00) as well as medically indicated (aOR=0.98; 95% CI 0.98, 0.99) PTB. Among medically indicated PTB, plasma folate concentration in the highest quartile was associated with a reduction in the odds of PTB; this relationship did not reach statistical significance for spontaneous PTB. Plasma folate concentrations in excess of 45.3 nmol/l were associated with a 30% reduction in the odds of spontaneous (aOR=0.72; 95% CI 0.55, 0.95) and medically indicated PTB (aOR=0.58; 95% CI 0.40, 0.82).

## Discussion

In our full sample, multivitamin supplement intake and plasma folate concentrations were generally adequate or



**Table 2** Relationship between multivitamin supplement intake and preterm birth (PTB) among predominantly urban, low-income, minority mother–infant dyads (*n* 7576) enrolled in the Boston Birth Cohort, USA, from 1998 to 2014

Period	Term ( <i>n</i> 5507)		PTB ( <i>n</i> 2069)		Unadjusted		Adjusted OR*	
	<i>n</i> <sub>cases</sub>	%	<i>n</i> <sub>cases</sub>	%	OR	95% CI	OR	95% CI
Multivitamin supplement intake in pregnancy (first to third trimester)								
Continuous (index)†	n/a	n/a	n/a	n/a	0.97	0.96, 0.98	0.98	0.97, 0.99
Categorical								
None (ref.)	436	7.9	219	10.6	1.00	n/a	1.00	n/a
1–2 times/week	933	16.9	406	19.6	0.87	0.71, 1.06	0.91	0.74, 1.12
3–5 times/week	1373	24.9	476	23.0	0.69	0.57, 0.84	0.78	0.64, 0.96
> 5 times/week	2765	50.2	968	46.8	0.70	0.58, 0.83	0.77	0.64, 0.93
Multivitamin supplement intake in specific time periods								
Preconception								
None (ref.)	5137	93.3	1940	93.8	1.00	n/a	1.00	n/a
Any	370	6.7	129	6.2	0.92	0.75, 1.14	0.90	0.72, 1.12
First trimester								
None (ref.)	914	16.6	402	19.4	1.00	n/a	1.00	n/a
1–2 times/week	204	3.7	97	4.7	1.08	0.83, 1.41	1.08	0.82, 1.43
3–5 times/week	1582	26.9	539	26.1	0.83	0.71, 0.96	0.90	0.76, 1.06
> 5 times/week	2907	52.8	1031	49.8	0.81	0.70, 0.92	0.85	0.73, 0.98
Second trimester								
None (ref.)	642	11.7	290	14.0	1.00	n/a	1.00	n/a
1–2 times/week	220	4.0	108	5.2	1.09	0.83, 1.42	1.19	0.90, 1.57
3–5 times/week	1558	28.3	570	27.6	0.81	0.68, 0.96	0.92	0.77, 1.10
> 5 times/week	3087	56.1	1101	53.2	0.79	0.68, 0.92	0.86	0.73, 1.02
Third trimester								
None (ref.)	655	11.9	345	16.8	1.00	n/a	1.00	n/a
1–2 times/week	255	4.6	99	4.8	0.74	0.56, 0.96	0.80	0.61, 1.06
3–5 times/week	1558	28.3	543	26.2	0.66	0.56, 0.78	0.75	0.63, 0.90
> 5 times/week	3039	55.2	1082	52.3	0.68	0.58, 0.78	0.75	0.64, 0.87

ref., reference category; n/a, not applicable.

\*Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, parity, cigarette use, alcohol use, stress, pre-eclampsia disorders, intra-uterine infection/inflammation and diabetes mellitus.

†Composite measure of supplement intake from first to third trimester.

**Table 3** Relationship between maternal plasma folate levels and preterm birth (PTB) among predominantly urban, low-income, minority mother–infant dyads (*n* 2313) enrolled in the Boston Birth Cohort, USA, from 1998 to 2014

Plasma folate level	Term ( <i>n</i> 1593)		PTB ( <i>n</i> 720)		Unadjusted		Adjusted OR*	
	<i>n</i> <sub>cases</sub>	%	<i>n</i> <sub>cases</sub>	%	OR	95% CI	OR	95% CI
Continuous plasma folate concentration (nmol/l)								
Each unit increase†	n/a	n/a	n/a	n/a	0.991	0.986, 0.995	0.994	0.990, 0.999
Each interquartile increase in folate level‡	n/a	n/a	n/a	n/a	0.81	0.73, 0.90	0.88	0.79, 0.97
Quartiles of plasma folate concentration (nmol/l)								
Lowest quartile: 6.6–19.4 (ref.)	378	23.7	201	27.9	1.00	n/a	1.00	n/a
Second quartile: 19.4–30.0	386	24.2	192	26.7	0.94	0.73, 1.19	1.02	0.79, 1.33
Third quartile: 30.0–43.8	393	24.7	185	25.7	0.89	0.69, 1.13	1.09	0.83, 1.42
Highest quartile: 43.8–185.5	436	27.4	142	19.7	0.61	0.47, 0.79	0.74	0.56, 0.97
WHO classification (nmol/l)								
Insufficiency/deficiency: <13.5	155	9.7	82	11.4	1.07	0.80, 1.43	0.86	0.63, 1.18
Normal: 13.5–45.3 (ref.)	1030	64.7	508	70.6	1.00	n/a	1.00	n/a
Excess: >45.3	408	25.6	130	18.1	0.65	0.52, 0.81	0.70	0.55, 0.89

ref., reference category; n/a, not applicable.


\*Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, parity, tobacco use, alcohol use, stress, BMI, pre-eclampsia disorders, intra-uterine infection/inflammation, and diabetes.

†Mean (sd) for term birth and PTB: 36.6 (24.7) and 32.3 (20.0) nmol/l, respectively.

‡Median (interquartile range) for term birth and PTB: 31.5 (20.8–45.6) and 28.5 (19.0–38.5) nmol/l, respectively.

high, as expected in this era of mandatory folic acid fortification of the food supply. Still, about a quarter of women had a relatively low plasma folate concentration (<19.4 nmol/l), which was associated with an increased risk of PTB. While there are no national data, an association between folate fortification and reduced PTB rates

was observed in California among live births that occurred from January 1990 through December 2000<sup>(13)</sup>. After adjusting for maternal age, parity, race/ethnicity, education, year of birth and fortification period, fortification was shown to reduce PTB risk (relative risk ratio = 0.96; 95% CI 0.94, 0.97).



**Fig. 1** Probability (solid line) and 95% confidence interval (dashed lines) of (a) overall, (b) spontaneous and (c) medically indicated preterm birth (PTB) by plasma folate concentration among predominantly urban, low-income, minority mother–infant dyads ( $n$  2313) enrolled in the Boston Birth Cohort, USA, from 1998 to 2014

After controlling for confounding factors, our analysis shows that multivitamin supplement intake of at least 3 times/week throughout pregnancy was significantly associated with a reduction in the odds of PTB, consistent with other US-based prospective studies that have assessed dietary folate intake<sup>(14,16)</sup>. A study in a low-income minority population showed that low ( $\leq 240$   $\mu\text{g}/\text{d}$ ) and intermediate (241–400  $\mu\text{g}/\text{d}$ ) dietary folate intake were associated with an increased risk of PTB, respectively, as compared with women who had a folate intake

$>400$   $\mu\text{g}/\text{d}$ <sup>(14)</sup>. In another study, dietary folate intake  $\leq 500$   $\mu\text{g}/\text{d}$  was associated with an almost two times greater risk of preterm delivery<sup>(16)</sup>.

We note that there was no significant association between preconceptional supplement intake and PTB, contrary to the findings of Bukowski *et al.*, which demonstrated a 50–70% related reduction in the incidence of early spontaneous PTB<sup>(18)</sup>. However, in our study, preconception supplement intake was very low (7.1%) and may have resulted in reduced statistical power to detect significant associations. Multivitamin supplementation in the first and third trimester were both significantly associated with reduced PTB odds, with use during the third trimester associated with a greater reduction in PTB odds than use during the first trimester. It is unclear why second-trimester multivitamin supplement intake is not associated with PTB. While the association observed in the third trimester may be a reflection of intake in other trimesters given the high correlation across trimesters, these findings suggest that the third trimester may be a critical time window in the folate–PTB relationship. While folate is needed for maternal tissue and fetal and placental growth throughout pregnancy, the rapid fetal development occurring during the third trimester is associated with maximum folate catabolism and thus increased requirements during this critical period<sup>(29,30)</sup>. Studies show that women who stopped multivitamin or folate supplementation after the first trimester had lower concentrations of maternal serum and red-blood-cell folate<sup>(29–31)</sup>. The association between multivitamin supplement intake and PTB was corroborated using plasma folate concentration at delivery. Increasing plasma folate concentrations significantly reduced the odds of PTB. Our findings are consistent with other US-based studies with folate measurements during pregnancy, wherein each 1 nmol/l increase in serum folate concentration at 28 weeks of gestation was also associated with reduced risk of PTB<sup>(14)</sup> and serum folate concentration less than 36.9 nmol/l in the second trimester (24–29 weeks of gestation) led to a nearly twofold increased risk of PTB<sup>(16)</sup>. These findings demonstrating the relationship between maternal folate status and PTB are particularly important given that the national PTB rates have remained high, 10.4% in 2007 and 9.8% in 2016, despite research and intervention efforts<sup>(32)</sup>. Our research on a predominantly minority population is also appropriate given that the national PTB rate was highest among non-Hispanic Black births (13.8%)<sup>(32)</sup>. The patient population from which we derived the Boston Birth Cohort has a high rate of PTB (15–17%) and the higher rates of PTB seen in the study sample are because the study oversampled PTB at enrolment. Among this population at a particular high risk of PTB and inadequate folate intake, we have shown that, in such a setting, the lower levels of plasma folate with preterm delivery may be a reflection of the duration of folic acid supplementation and that maternal adequate folate status can reduce the risk of PTB<sup>(33)</sup>.

**Table 4** Plasma folate levels and unadjusted and adjusted odds of preterm birth (PTB) subtypes among predominantly urban, low-income, minority mother–infant dyads (*n* 2313) enrolled in the Boston Birth Cohort, USA, from 1998 to 2014

Plasma folate level	Spontaneous PTB				Medically indicated PTB			
	<i>n</i> <sub>cases</sub>	%	aOR*	95 % CI	<i>n</i> <sub>cases</sub>	%	aOR†	95 % CI
Continuous plasma folate concentration (nmol/l)								
Each unit increase	n/a	n/a	0.995	0.990, 1.000	n/a	n/a	0.99	0.98, 0.99
Each interquartile increase in folate level	n/a	n/a	0.90	0.80, 1.01	n/a	n/a	0.73	0.62, 0.87
Quartiles of plasma folate concentration (nmol/l)								
Lowest quartile: 6.6–19.4 (ref.)	114	23.2	1.00	n/a	87	18.7	1.00	n/a
Second quartile: 19.4–30.0	119	23.6	1.12	0.82, 1.53	73	15.9	0.85	0.60, 1.21
Third quartile: 30.0–43.8	124	24.0	1.27	0.93, 1.73	61	13.4	0.68	0.47, 0.99
Highest quartile: 43.8–185.5	96	18.1	0.86	0.62, 1.18	46	9.5	0.46	0.31, 0.69
WHO classification (nmol/l)								
Insufficiency/deficiency: <13.5	45	22.5	0.77	0.53, 1.12	37	19.3	1.25	0.83, 1.86
Normal: 13.5–45.3 (ref.)	321	23.8	1.00	n/a	187	15.4	1.00	n/a
Excess: ≥45.3	87	17.6	0.72	0.55, 0.95	43	9.5	0.58	0.40, 0.82

aOR, adjusted odds ratio; ref., reference category; n/a, not applicable.

\*Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, parity, tobacco use, alcohol use, stress, BMI, pre-eclampsia disorders, intra-uterine infection/inflammation and diabetes.

†Adjusted for maternal race, age, nativity, education, marital status, receipt of public assistance, parity, tobacco use, alcohol use and stress.

Maternal factors well demonstrated in the literature to be associated with, but not necessarily in the causal pathway of PTB include demographic, obstetric, medical and psychosocial risk factors<sup>(34)</sup>. However, the underlying mechanisms for the link between folate and PTB are not well understood but appear to be biologically plausible. For example, variations in key genes involved in folate metabolism, such as those encoding dihydrofolate reductase (DHFR) and serine hydroxymethyltransferase (SHMT1), appear to increase the risk for spontaneous PTB<sup>(35)</sup>. Other mechanistic pathways that may explain the folate–PTB relationship include hyperhomocysteinaemia, placental implantation and intra-uterine infection and inflammation<sup>(36,37)</sup>. Low folate status is associated with hyperhomocysteinaemia, which has been linked with increased arterial stiffness, insulin resistance and endothelial dysfunction. Folate may also affect placental implantation and vascular remodelling through its role as a superoxide scavenger in antioxidant defences<sup>(36)</sup>. Folate deficiency is also associated with abnormal inflammatory responses, which could conceivably trigger premature parturition in the context of intra-uterine infection<sup>(38,39)</sup>.

Strengths of our study include the use of complementary measures of folate status, from maternal self-report (capturing pattern of long-term use) and more objective biomarkers, providing multi-measure consistent evidence to support the folate–PTB relationship. The study is the largest investigation with recent birth cohort data on plasma folate and PTB published to date and is the first one that performed PTB subtype analyses. While maternal folate status has been linked with spontaneous PTB<sup>(18)</sup>, its relationship with medically indicated PTB has been demonstrated only in animal studies<sup>(40)</sup>. Again, such research is particularly relevant among high-risk populations such as non-Hispanic Blacks who have lower folate levels compared with other race/ethnic groups<sup>(8)</sup> and a higher proportion of medically indicated PTB<sup>(41)</sup>.

Our study contributes new knowledge to the field by exploring specific patterns of multivitamin supplementation during the preconception period and across trimesters. This facilitates identifying the critical period over the course of pregnancy to reinforce adequate folate intake in order to reduce PTB. Finally, our study focuses on the high-risk non-Hispanic Black US populations in need for interventions to address both PTB and lower folate status.

However, we acknowledge some limitations of the present study. While plasma or serum folate is a common inexpensive measurement used in clinical and research settings, it reflects only short-term folate status within the past few days in contrast to red-cell-folate concentrations which measure long-term folate status. Thus, plasma folate concentration at delivery can be used as a proxy only for third-trimester folate concentration<sup>(42)</sup>. As shown in a previous publication<sup>(21)</sup>, maternal self-reported multivitamin intake during the third trimester was positively associated with maternal plasma folate levels. While folate measurements during early pregnancy would be more ideal, plasma folate concentration at delivery can be used as a proxy for third-trimester folate concentration. In addition, multivitamin supplement intake was based on self-report, which is subject to recall bias as well as the fact that there was no information on the actual dosage of folic acid consumed. Also, the determination of folate status based on the frequency of supplement intake may be incomplete, since folate status may also be influenced by dietary intake of folate-rich/fortified foods and other factors affecting folate metabolism. Due to the high correlations between multivitamin supplement intake across all trimesters ( $\rho = 0.58\text{--}0.85$ ,  $P < 0.001$ ), further adjustments for intake during other trimesters were not conducted when we explored the associations in each trimester. This was an observational study enriched by PTB, and by its nature cannot enable causal inference<sup>(43)</sup> as unobserved or uncontrolled confounding remains a threat to validity.



Additional detail on some of the confounding variables, such as the level of cigarette and alcohol consumption in each trimester, would have been helpful. While no randomized controlled trial has been conducted in the USA and is unlikely given the advantageous role of folate on pregnancy outcomes, study findings need to be confirmed in other nationally representative prospective longitudinal studies. This is a US urban low-income population in a post-folate fortification context and caution is needed in generalizing study findings to other populations with different characteristics. We also acknowledge that ours is a high-risk (low-income, minority, urban) US population in a post-folate fortification context and that our findings may be reproducible in other populations in other countries.

There are important implications to be gleaned from the present study. The association between folate and PTB among this predominantly minority, urban low-income population is important, because studies have shown that women who were non-White (non-Hispanic Black and Hispanic women), aged 18–24 years, and had less than a high-school education or had an annual household income of <\$US 25 000 are the least likely to report daily consumption of a supplement containing folic acid<sup>(44)</sup>. In addition, minority populations are less likely to have heard about folic acid, to know it can prevent birth defects, and to consume foods fortified with folic acid or take vitamins containing folic acid<sup>(45,46)</sup>.

Lastly, our study supports the importance of consistent folate intake throughout pregnancy to mitigate adverse pregnancy outcomes, including PTB<sup>(9,29,47)</sup>. Our study demonstrated minimal difference in PTB mitigation related to multivitamin supplement intake of 3–5 times/week *v.* >5 times/week, suggesting a possible threshold dosing schedule of 3 times/week. If corroborated by other studies, this finding may impact the recommendations for frequency of multivitamin supplement intake before and during pregnancy. Specifically, this finding suggests that the same protective benefit can be derived from a three times weekly dose compared with a daily dose. Finally, folate has a broad biological function and there is increasing recognition that folate supplementation during pregnancy may affect both short-term and long-term health of the offspring. For example, in the same cohort, we demonstrated beneficial effects of adequate maternal plasma folate levels on offspring obesity<sup>(48,49)</sup>. Furthermore, our recent study<sup>(21)</sup> along with that of others<sup>(50)</sup> raised concern about the potential risk of extremely high levels of folate on autism. Therefore, more work remains to be done to determine the optimal range of maternal folate levels throughout pregnancy for major organs and systems in the offspring. Ultimately, we need to define an optimal range of folate levels (neither too low nor too high), preconception and during pregnancy, which can maximize its health benefits and minimize its risk. This may require careful consideration of a woman's health conditions, dietary intake and folic acid

supplementation, and measurement of plasma folate levels as needed.

## Acknowledgements

*Financial support:* The Boston Birth Cohort (the parent study) was supported in part by the March of Dimes Perinatal Epidemiological Research Initiative (grant numbers 20-FY02-56, 21-FY07-605); the National Institutes of Health (NIH) (grant numbers R21ES011666, R01HD041702, R21HD066471, U01AI090727, R21AI079872 and R01HD086013); and the Health Resources and Services Administration (HRSA) of the US Department of Health and Human Services (HHS) (grant numbers R40MC27443 and UJ2MC31074). The authors are also grateful for general support from the Hopkins Population Center (grant number NICHD R24HD042854). This information or content and conclusions are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by, any funding agencies. The funding agencies had no role in the design, analysis or writing of this article. *Conflict of interest:* None of the authors reported a conflict of interest related to the study. *Authorship:* B.O., A.Sa. and X.W. designed the research; B.O., R.R. and Y.J. performed statistical analyses; G.W., X.H. and Y.J. performed lab assays; B.O. wrote the paper; and all other co-authors participated in data interpretation and presentation, critical review and revision of the manuscript. X.W. is the Principal Investigator of the Boston Birth Cohort and had primary responsibility for final content. All authors approved the final manuscript for submission. *Ethics of human subject participation:* This study was conducted according to the guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects were approved by Institutional Review Boards of Boston University Medical Center and the Johns Hopkins Bloomberg School of Public Health. Written informed consent was obtained from all subjects.

## Supplementary material

To view supplementary material for this article, please visit <https://doi.org/10.1017/S1368980018003221>

## References

1. Frey HA & Klebanoff MA (2016) The epidemiology, etiology, and costs of preterm birth. *Semin Fetal Neonatal Med* **21**, 68–73.
2. Bailey LB & Gregory JF 3rd (1999) Folate metabolism and requirements. *J Nutr* **129**, 779–782.
3. Smits LJ & Essed GG (2001) Short interpregnancy intervals and unfavourable pregnancy outcome: role of folate depletion. *Lancet* **358**, 2074–2077.
4. Zhu BP (2005) Effect of interpregnancy interval on birth outcomes: findings from three recent US studies. *Int J Gynecol Obstet* **89**, Suppl. 1, S25–S33.

5. Moussa HN, Hosseini Nasab S, Haidar ZA *et al.* (2016) Folic acid supplementation: what is new? Fetal, obstetric, long-term benefits and risks. *Future Sci OA* **2**, FSO116.
6. Pfeiffer CM, Johnson CL, Jain RB *et al.* (2007) Trends in blood folate and vitamin B-12 concentrations in the United States, 1988–2004. *Am J Clin Nutr* **86**, 718–727.
7. Crider KS, Bailey LB & Berry RJ (2011) Folic acid food fortification – its history, effect, concerns, and future directions. *Nutrients* **3**, 370–384.
8. Tinker SC, Hamner HC, Qi YP *et al.* (2015) US women of childbearing age who are at possible increased risk of a neural tube defect-affected pregnancy due to suboptimal red blood cell folate concentrations, National Health and Nutrition Examination Survey 2007 to 2012. *Birth Defects Res A Clin Mol Teratol* **103**, 517–526.
9. Czeizel AE, Dudas I, Vereczkey A *et al.* (2013) Folate deficiency and folic acid supplementation: the prevention of neural-tube defects and congenital heart defects. *Nutrients* **5**, 4760–4775.
10. Blom HJ (2009) Folic acid, methylation and neural tube closure in humans. *Birth Defects Res A Clin Mol Teratol* **85**, 295–302.
11. Smithells RW, Sheppard S, Schorah CJ *et al.* (1980) Possible prevention of neural-tube defects by periconceptional vitamin supplementation. *Lancet* **1**, 339–340.
12. Bibbins-Domingo K, Grossman DC, Curry SJ *et al.* (2017) Folic acid supplementation for the prevention of neural tube defects: US Preventive Services Task Force Recommendation Statement. *JAMA* **317**, 183–189.
13. Shaw GM, Carmichael SL, Nelson V *et al.* (2004) Occurrence of low birthweight and preterm delivery among California infants before and after compulsory food fortification with folic acid. *Public Health Rep* **119**, 170–173.
14. Scholl TO, Hediger ML, Schall JI *et al.* (1996) Dietary and serum folate: their influence on the outcome of pregnancy. *Am J Clin Nutr* **63**, 520–525.
15. Scholl TO & Johnson WG (2000) Folic acid: influence on the outcome of pregnancy. *Am J Clin Nutr* **71**, 5 Suppl., 1295S–1303S.
16. Siega-Riz AM, Savitz DA, Zeisel SH *et al.* (2004) Second trimester folate status and preterm birth. *Am J Obstet Gynecol* **191**, 1851–1857.
17. Bodnar LM, Himes KP, Venkataramanan R *et al.* (2010) Maternal serum folate species in early pregnancy and risk of preterm birth. *Am J Clin Nutr* **92**, 864–871.
18. Bukowski R, Malone FD, Porter FT *et al.* (2009) Pre-conceptional folate supplementation and the risk of spontaneous preterm birth: a cohort study. *PLoS Med* **6**, e1000061.
19. Dunlop AL, Taylor RN, Tangpricha V *et al.* (2012) Maternal micronutrient status and preterm versus term birth for black and white US women. *Reprod Sci* **19**, 939–948.
20. Shaw GM, Carmichael SL, Yang W *et al.* (2011) Periconceptional intake of folic acid and food folate and risks of preterm delivery. *Am J Perinatol* **28**, 747–752.
21. Raghavan R, Riley AW, Volk H *et al.* (2017) Maternal multivitamin intake, plasma folate and vitamin B<sub>12</sub> levels and autism spectrum disorder risk in offspring. *Paediatr Perinat Epidemiol* **32**, 100–111.
22. Surkan PJ, Dong L, Ji Y *et al.* (2017) Paternal involvement and support and risk of preterm birth: findings from the Boston Birth Cohort. *J Psychosom Obstet Gynaecol*. Published online: 16 November 2017. doi: 10.1080/0167482X.2017.1398725.
23. Wang X, Zuckerman B, Pearson C *et al.* (2002) Maternal cigarette smoking, metabolic gene polymorphism, and infant birth weight. *JAMA* **287**, 195–202.
24. Blumenfeld YJ, El-Sayed YY, Lyell DJ *et al.* (2015) Risk factors for prolonged postpartum length of stay following cesarean delivery. *Am J Perinatol* **32**, 825–832.
25. Organisation for Economic Co-operation and Development (2014) *Average Length of Stay: Childbirth 2014/1*. Paris: OECD Publishing.
26. Greenberg JA & Bell SJ (2011) Multivitamin supplementation during pregnancy: emphasis on folic acid and l-methylfolate. *Rev Obstet Gynecol* **4**, 126–127.
27. Huo Y, Li J, Qin X *et al.* (2015) Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. *JAMA* **313**, 1325–1335.
28. World Health Organization (2015) *Serum and Red Blood Cell Folate Concentrations for Assessing Folate Status in Populations*. Geneva: WHO.
29. Wang S, Ge X, Zhu B *et al.* (2016) Maternal continuing folic acid supplementation after the first trimester of pregnancy increased the risk of large-for-gestational-age birth: a population-based birth cohort study. *Nutrients* **8**, 493.
30. Chanarin I, Rothman D, Ward A *et al.* (1968) Folate status and requirement in pregnancy. *Br Med J* **2**, 390–394.
31. McNulty B, McNulty H, Marshall B *et al.* (2013) Impact of continuing folic acid after the first trimester of pregnancy: findings of a randomized trial of folic acid supplementation in the second and third trimesters. *Am J Clin Nutr* **98**, 92–98.
32. Hamilton BE, Martin JA, Osterman MJ *et al.* (2017) *Births: Provisional Data for 2016*. *Vital Statistics Rapid Release Report* no. 2. Hyattsville, MD: National Center for Health Statistics.
33. Cheng TL, Mistry KB, Wang G *et al.* (2018) Folate nutrition status in mothers of the Boston Birth Cohort, sample of a US urban low-income population. *Am J Public Health* **108**, 799–807.
34. Behrman RE & Butler AS (editors) (2007) *Preterm Birth: Causes, Consequences, and Prevention*. Washington, DC: National Academies Press.
35. Johnson WG, Scholl TO, Spychala JR *et al.* (2005) Common dihydrofolate reductase 19-base pair deletion allele: a novel risk factor for preterm delivery. *Am J Clin Nutr* **81**, 664–668.
36. Chen LW, Lim AL, Colega M *et al.* (2015) Maternal folate status, but not that of vitamins B-12 or B-6, is associated with gestational age and preterm birth risk in a multiethnic Asian population. *J Nutr* **145**, 113–120.
37. Bergen N, Jaddoe V, Timmermans S *et al.* (2012) Homocysteine and folate concentrations in early pregnancy and the risk of adverse pregnancy outcomes: the Generation R Study. *BJOG* **119**, 739–751.
38. Cunningham F, Leveno K, Bloom S *et al.* (2004) *Williams Obstetrics*, 24th ed. New York: McGraw-Hill Education/Medical.
39. Courtemanche C, Elson-Schwab I, Mashiyama ST *et al.* (2004) Folate deficiency inhibits the proliferation of primary human CD8+T lymphocytes *in vitro*. *J Immunol* **173**, 3186–3192.
40. Zhao M, Chen YH, Dong XT *et al.* (2013) Folic acid protects against lipopolysaccharide-induced preterm delivery and intrauterine growth restriction through its anti-inflammatory effect in mice. *PLoS One* **8**, e82713.
41. Ananth CV & Vintzileos AM (2006) Epidemiology of preterm birth and its clinical subtypes. *J Matern Fetal Neonatal Med* **19**, 773–782.
42. Farrell C-JL, Kirsch SH & Herrmann M (2013) Red cell or serum folate: what to do in clinical practice? *Clin Chem Lab Med* **51**, 555–569.
43. Szklo M & Nieto FJ (2014) *Epidemiology: Beyond the Basics*. Burlington, MA: Jones & Bartlett Publishers.
44. Saccone G, Sarno L, Roman A *et al.* (2016) 5-Methyltetrahydrofolate in prevention of recurrent preeclampsia. *J Matern Fetal Neonatal Med* **29**, 916–920.
45. Yang QH, Carter HK, Mulinare J *et al.* (2007) Race-ethnicity differences in folic acid intake in women of childbearing

- age in the United States after folic acid fortification: findings from the National Health and Nutrition Examination Survey, 2001–2002. *Am J Clin Nutr* **85**, 1409–1416.
46. Ahluwalia IB & Daniel KL (2001) Are women with recent live births aware of the benefits of folic acid? *MMWR Recomm Rep* **50**, 3–14.
  47. Higgins JR, Quinlivan EP, McPartlin J *et al.* (2000) The relationship between increased folate catabolism and the increased requirement for folate in pregnancy. *BJOG* **107**, 1149–1154.
  48. Wang G, Hu FB, Mistry KB *et al.* (2016) Association between maternal prepregnancy body mass index and plasma folate concentrations with child metabolic health. *JAMA Pediatr* **170**, e160845.
  49. Wang H, Mueller NT, Li J *et al.* (2017) Association of maternal plasma folate and cardiometabolic risk factors in pregnancy with elevated blood pressure of offspring in childhood. *Am J Hypertens* **30**, 532–540.
  50. Wiens D & DeSoto M (2017) Is high folic acid intake a risk factor for autism? – A review. *Brain Sci* **7**, 149.